Extended-Release Tacrolimus Following Liver Transplantation

Launched by UNIVERSITY OF ALBERTA · Feb 15, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a new formulation of a medication called Tacrolimus, specifically looking at a version known as Envarsus, for patients who have received a liver transplant. The goal is to see if this new version can help prevent complications while causing fewer side effects compared to the traditional form of Tacrolimus. Common side effects from the standard medication can include kidney problems, headaches, high blood pressure, and diabetes, among others. The researchers will monitor how safe and effective the new medication is, as well as how well it helps the liver function and reduces hospital visits after the transplant.

To participate in the trial, you need to be an adult who has undergone a liver transplant at the University of Alberta. There are some specific medical conditions that may exclude you, such as serious heart rhythm issues or significant kidney problems. If you join the trial, you can expect regular check-ups and assessments to track your health and the medication's effects. The hope is that this research will lead to better care and outcomes for patients who have had a liver transplant.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • - Adult individuals transplanted at the University of Alberta
• Exclusion Criteria:
• • Individuals with congenital long QT syndrome
• • Patients with elevated bilirubin \> 100 umol/L post-LT (at day 3)
• • Patients with chronic kidney disease (eGFR \< 45 ml per minute per 1.73 m2)
• • Patients with acute kidney injury requiring discontinuation of calcineurin inhibitors.
• • Patients who have hepatocellular carcinoma, require a re-transplant, or receive multi-visceral transplant